The immune checkpoint inhibitors (ICIs), including anti‐PD1 or anti‐CTLA‐4 were widespread used in the second‐line therapy of HCC and other tumors.19, 20, 21. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.